



Functional Implications of DNA Methylation in Adipose Biology

Xiang Ma and Sona Kang

Diabetes 2019;68:871–878 | <https://doi.org/10.2337/dbi18-0057>

The twin epidemics of obesity and type 2 diabetes (T2D) are a serious health, social, and economic issue. The dysregulation of adipose tissue biology is central to the development of these two metabolic disorders, as adipose tissue plays a pivotal role in regulating whole-body metabolism and energy homeostasis (1). Accumulating evidence indicates that multiple aspects of adipose biology are regulated, in part, by epigenetic mechanisms. The precise and comprehensive understanding of the epigenetic control of adipose tissue biology is crucial to identifying novel therapeutic interventions that target epigenetic issues. Here, we review the recent findings on DNA methylation events and machinery in regulating the developmental processes and metabolic function of adipocytes. We highlight the following points: 1) DNA methylation is a key epigenetic regulator of adipose development and gene regulation, 2) emerging evidence suggests that DNA methylation is involved in the trans-generational passage of obesity and other metabolic disorders, 3) DNA methylation is involved in regulating the altered transcriptional landscape of dysfunctional adipose tissue, 4) genome-wide studies reveal specific DNA methylation events that associate with obesity and T2D, and 5) the enzymatic effectors of DNA methylation have physiological functions in adipose development and metabolic function.

EPIGENETIC CHANGES ARE LINKED TO OBESITY AND TYPE 2 DIABETES

Obesity and type 2 diabetes (T2D) are highly complex human diseases, and genetics plays an important role in the etiology of both. With the advent of next-generation sequencing, several common single nucleotide polymorphisms (SNPs) have been discovered in association with disease susceptibility. However, the vast majority of these

variants have not been tested for causality, and even if proven causal, they cannot fully explain many clinical features such as high heritability, high discordance in adult monozygotic twins, and the close relationship with environmental factors (2–5). Therefore, it has long been speculated that nongenetic variation, such as epigenetic alterations, plays a role in pathogenesis. This notion has been borne out by a recent epigenome-wide association study that linked alterations in DNA methylation to whole-body insulin sensitivity (6).

DNA methylation is a reversible epigenetic mark involving the covalent transfer of a methyl group to the C-5 position of a cytosine residue by DNA methyltransferases (DNMTs), usually in the context of a cytosine-guanine dinucleotide (CpG) doublet. Though methylated DNA has long been thought to be a static mark, recent studies indicate that methylated DNA undergoes dynamic and reversible remodeling through DNA demethylases, namely, the ten-eleven translocation (TET) proteins. Mounting evidence supports that DNA methylation is involved in various forms of metabolic perturbation, from the abnormal development of adipose tissue to the dysfunction of adult adipocytes. Here, we will discuss the DNA methylation events that impact metabolism and the functional roles of DNMTs and TET proteins in adipose biology, with an emphasis on those that may be associated with obesity and T2D.

DNA METHYLATION AND ITS MACHINERY

DNA methylation is a process by which methyl groups are added to the DNA molecule, especially at the 5 carbon of the cytosine ring, which forms 5-methylcytosine (5mC) (7). In mammals, 5mC is mostly found in the context of paired symmetrical methylation of a CpG site, a site in which a cytosine is located next to a guanidine (7). However, non-CpG methylation is also detected in human

and other species (8–10). In the bulk of genomic DNA, most CpGs are methylated, whereas those located in a CpG island (where CpG sites cluster to form repetitive sequences) remain largely unmethylated (7).

DNA methylation is mediated by DNMTs. In mammals, five family members of the DNMT proteins have been characterized—*Dnmt1*, -2, -3a, -3b, and -3L—yet only the first three possess DNMT activity (11). DNMT1 is the maintenance Dnmt for replication, whereas DNMT3a and -3b are referred as de novo DNMTs, as they can establish a new DNA methylation pattern (11). The DNMT3-like protein *Dnmt3L* is homologous to the other *Dnmt3s* but lacks catalytic activity, and *Dnmt2* has sequence homology to all Dnmts but methylates cytoplasmic tRNA instead of DNA (11).

DNA methylation has long been thought to be a static epigenetic mark, but emerging evidence suggests that it undergoes dynamic and reversible remodeling in somatic cells during developmental and pathogenic processes (12,13), making its machinery and effects attractive drug targets. For example, DNA methylation can be erased by either passive or active mechanisms or a combination of both (14). Passive demethylation is often due to the loss of 5mC during successive rounds of replication in the absence of methylation maintenance machinery such as DNMT1. By contrast, active demethylation is mediated by a set of enzymes; TET proteins (TET1, -2, and -3) oxidize 5mC to hydroxymethylcytosine (5hmC), which is then converted to unmethylated cytosine (5C) through base excision repair and thymidine DNA glycosylase (15).

The biological importance of DNA methylation as a major type of epigenetic modification in regulating gene expression has been well established. In general, reduced DNA methylation in the promoter or other gene regulatory regions is associated with increased DNA binding of transcription factors and chromatin proteins, thus allowing gene transcription to occur (16). By contrast, increased

DNA methylation at the regulatory regions is often associated with gene repression (17).

DNA METHYLATION IN ADIPOGENESIS

DNA methylation plays an important role in a broad scope of developmental processes including adipogenesis (18–21). Inhibiting DNMT in multipotent C3H10T1/2 cells and 3T3-L1 preadipocytes stimulates spontaneous differentiation and enhances differentiation in response to adipogenic inducers (22,23). However, genetic studies have conflicting results with regard to the exact role of DNMTs in adipogenesis. DNMT1 is crucial for maintaining DNA methylation and repressive histone H3K9 methylation patterns prior to differentiation, suggesting it represses 3T3-L1 adipogenesis (24). However, knocking down *Dnmt1* and -3a impairs 3T3-L1 adipogenesis (25). This discrepancy might be due to the experimental conditions and tissue culture variables between the two laboratory environments. In another controversy, it was found that, in late-stage differentiation, DNMT inhibition promoted lipid accumulation by enhancing lipogenesis by upregulating the lipogenic transcription factor *Srebp1c* (25). By contrast, other groups reported that DNMT inhibition reduced adipogenic capacity in 3T3-L1 and ST2 mesenchymal precursor cell lines by upregulating canonical Wnt signaling (21,26).

Fortunately, there is more consensus in the field about the DNA methylation profile of key adipocyte genes during differentiation (Fig. 1). PPAR γ is expressed mainly in adipose tissue, where it regulates fatty acid storage and glucose metabolism, and C/EBP is involved in adipogenesis. The promoters of both genes are gradually demethylated during 3T3-L1 adipogenesis, correlating with increased expression of the genes (27,28). This coincides with the loss of repressive histone marks (H3K9me3) and the gain of active marks (e.g., H3K27ac and H3K4me3) (28), although the regulation of this timing is not clearly




Figure 1—Summary of the relationship between environmental factors and DNA (de)methylation machinery in the regulation of adipose biology. Various perturbations from environmental cues affect the expression or activity of DNMTs and TETs, which alters the DNA methylation profile of specific target genes with concordant changes in gene expression and phenotypic changes in adipose biology. The dotted line is used to depict relationships with weaker evidence. Small arrow inserts indicate the direction of change in DNA methylation at affected genes. Plus and minus signs indicate the direction of gene expression change.

understood. In addition, dexamethasone treatment causes *Cebpa* demethylation in C3H10T1/2 cells, with a concordant release of DNMT3a and -3b from the promoter (28). It is also noteworthy that the gene bodies of both *Pparg* and *Cebpa* are highly hypermethylated in embryonic stem cells to restrict lineage commitment to adipogenesis (29). Similarly, reduced DNA methylation is observed during adipogenesis at the promoters of other adipocyte genes (e.g., *Lep* [30], *Slc2a4* [GLUT4] [30], and *Peln* [27]). Intriguingly, recent global profiling studies have demonstrated that 5hmC (a cytosine that is an intermediate product of DNA demethylation) colocalizes with PPAR γ at enhancers in 3T3-L1 adipocytes (31), and PPAR γ -positive nuclei sorted from visceral adipose tissue from healthy humans are strongly coenriched with 5hmC (32). Given that the TET proteins, especially TET1 and TET2, are necessary for adipose conversion (33) and that PPAR γ physically interacts with them (27,34) indicate that PPAR γ is influencing the methylation pattern.

DNA methylation has also been implicated in the transgenerational regulation of adipose development. Maternal obesity predisposes offspring to obesity and T2D, yet the mechanisms remain unknown. A rodent study demonstrated that maternal obesity increases the expression of *Zfp423* (the key transcription factor committing cells to the adipocyte lineage [35] and maintaining white adipocyte identity [36]), which results from hypomethylation at the promoter region of *Zfp423*, which has exceptionally high density of CpGs in the promoter (37). Increased *Zfp423* expression implies increased adipose expansion but fewer beige/brown adipocytes, which can contribute to increased adiposity during fetal development and metabolic dysfunction later in life. Another mechanism for transgenerational regulation could be PPAR γ , which has reduced expression and function in obesity and adipose metabolic dysfunction. Offspring that are born to obese rat mothers have persistently lower PPAR γ expression, more epigenetic repression, including DNA hypermethylation, and reduced enrichment of active histone marks at the PPAR γ promoter region (38).

DNA (de)methylation governs brown adipocyte-specific gene regulation and development. In contrast to white adipocytes, which store excess energy in the form of triglycerides, brown and beige adipocytes dissipate energy in the form of heat. While white and brown adipose development share a similar genetic cascade, they have distinct transcriptional and epigenetic programs (39). A genome-wide study showed that the overall DNA methylation pattern of white adipocytes is different from that of brown (40). Compared with the white 3T3-L1 cell line, the brown adipocyte cell line HIB-1B has reduced methylation at the CpGs around cAMP response elements, which are important for the sympathetic stimulation of *Ucp1* expression, a marker gene for brown adipocytes that mediates adaptive thermogenesis (41). In 3T3-L1 adipocytes, the corepressor protein RIP140 recruits repressive histone modifiers, such as HDAC1 and -3, and all three DNMTs

to the *Ucp1* enhancer and promoter regions for gene repression (42). Consistently, treatment of 3T3-L1 and mouse embryonic fibroblasts with DNMT inhibitor increases *Ucp1* expression. Furthermore, TET-mediated DNA demethylation is required for the gene activation of *Prdm16*, an important transcriptional regulator of brown adipose development (43).

A more recent study reports that DNA methylation is involved in transgenerational regulation of brown and beige adipose activity (44). Interestingly, paternal cold exposure before mating results in improved systemic metabolism and protection from diet-induced obesity of the male offspring. Such transgenerational impact of cold exposure through male lineage was associated with differential methylation at multipole loci (44). Most prominently, the gene body of *Adrb3*, which encodes a protein mediating β -adrenergic stimulation in brown adipose tissue, was hypomethylated in association with increased gene expression in sperm genomic DNA (44). More studies should be conducted to understand the functional implication of DNA methylation in plasticity between beige and white adipocytes in response to various stimuli. Elucidating the epigenetic mechanisms of brown and beige adipose biology will shed light on effective therapeutic interventions for obesity and obesity-related human diseases.

Notably, a majority of these studies were conducted using tissue culture models. Although the results from in vitro studies provide important insights and are often conserved in vivo, the epigenome can profoundly differ between in vitro and in vivo contexts. Therefore, in vivo studies are required to better understand the physiological role of epigenetics in adipocyte commitment and developmental processes. Also, it will be important to investigate how distinct DNA methylation events interact with other epigenetic and transcriptional regulators to confer genomic target specificity and gene regulation.

DNA METHYLATION IN ADIPOCYTE FUNCTION

In obesity and obesity-related metabolic issues, adipokine regulation is profoundly altered (45), and some of these changes are regulated by DNA methylation (Table 1). Leptin is the key adipokine that mediates adipose tissue-brain communication to maintain energy homeostasis and normal body weight (46). Obesity is typically associated with high leptin levels and results in resistance to leptin (47). So far, the molecular and epigenetic mechanisms underlying that remain largely unknown.

Lep methylation is inversely correlated with adipocyte-specific *Lep* expression. For example, the *LEP* promoter is hypermethylated in the stromal vascular fraction but hypomethylated in the adipocyte fraction of human visceral adipose tissue (48). *Lep* promoter methylation decreases during mouse adipogenesis concurrently with increased *Lep* expression (49). Consistent with this, DNMT inhibition increases *LEP* expression in cell lines such as primary fibroblasts and HeLa cells (48).



Function	Adipogenesis	Obesity	Weight loss	Type 2 diabetes
Bone metabolism	-	<i>SPP1</i>	-	-
Energy balance	<i>LEP</i>	<i>LEP</i>	<i>LEP</i>	-
Glucogenesis	-	<i>PCK1</i>	-	-
Glucose homeostasis	-	-	-	<i>FGF21</i>
Hypoxia response	-	-	-	<i>HIF3A</i>
Inflammation	-	<i>CCL18</i>	<i>TNF</i>	-
Insulin sensitivity	<i>ADIPOQ</i>	<i>ADIPOQ</i>	-	-
Insulin signaling	-	<i>AKT2</i>	-	<i>IRS1</i>
Lipid droplet formation	<i>PLIN</i>	-	-	-
Obesity related	-	<i>FTO</i>	-	-
Potassium channel	-	-	-	<i>KCNQ1</i>
Transcription factor	<i>PPARG</i>	<i>TCF7L2, NANOG, OCT4, SOX2</i>	-	<i>PPARG</i>

Table 1—Summary of differential methylated loci in adipocytes in association with obesity and T2D.

Reduced *Lep* methylation could account for obesity-related leptin upregulation (49,50); however, the results have been inconsistent (51,52). Surprisingly, studies suggest that the *Lep* locus is hypermethylated in obesity. A high-fat diet regimen initially reduces *Lep* promoter methylation for up to 8 weeks, yet prolonged high-fat feeding for more than 12 and 14 weeks increases *Lep* methylation, especially in epididymal fat (53,54). This is accompanied by increased occupancy of DNMT1, DNMT3a, and DNMT3b at the *Lep* promoter (54). Similarly, long-term maternal high-fat feeding in rats results in increased birth weight, *Lep* hypermethylation, and increased plasma leptin levels in offspring (51). Diet-induced weight loss in obese female subjects accompanies *LEP* hypomethylation in association with increased *LEP* expression (48). By contrast, bariatric surgery-induced weight loss does not alter *LEP* methylation, though it decreases *LEP* expression (48). These results seem paradoxical and suggest that epigenetic modification occurs as a feedback regulatory mechanism due to increased *LEP* expression but is insufficient to normalize the expression. Further investigations are necessary to draw a general conclusion as to whether and how DNA methylation contributes to leptin gene regulation in various regimens of weight gain and loss.

Adiponectin is a protein hormone mainly produced by adipose tissue and is encoded by the *Adipoq/ADIPOQ* gene in mouse and human (55). It plays an important role in the maintenance of energy homeostasis by regulating glucose and lipid metabolism (56). Reduced circulating adiponectin level is correlated with obesity, insulin resistance, and T2D (55). Consistent with this, the *Adipoq* proximal promoter region is hypermethylated in obese mice (57) due to increased DNMT1

expression and activity. Moreover, systemic administration of DNMT inhibitor rescues adiponectin expression and improves glucose intolerance in high fat-fed wild-type mice (57). Human studies also support that *ADIPOQ* methylation in subcutaneous adipose tissue is positively correlated with BMI, waist girth, and fasting LDL cholesterol in plasma (58). *ADIPOQ* is also hypermethylated in the maternal adipose tissue of obese pregnant women, resulting in significantly lower plasma adiponectin levels (59).

Fibroblast growth factor 21 (FGF21) is well-known as a hepatokine, but it is also expressed in other tissues including fat and muscle (60). FGF21 facilitates glucose uptake in adipocytes (61–63) through unknown mechanisms. Adipocyte expression of *Fgf21* is negatively regulated by Dnmt3a, with concordant changes in DNA methylation in Dnmt3a gain- and loss-of-function models. Consistently, CpGs around *FGF21* are hypermethylated in adipose tissue from T2D patients with a negative correlation with FGF21 expression in adipose tissue (64).

Tumor necrosis factor α (TNF α) was traditionally considered to be secreted chiefly by macrophages, but it is also produced by other cell types including adipocytes (65). It is well established that circulating TNF α levels are positively correlated with insulin resistance in obesity (66). Contrary to what is expected, obese individuals with significant weight loss have decreased methylation at the promoter of *Tnf*. For instance, the obese women who lost more weight in a low-calorie diet intervention displayed lower promoter methylation levels of *Tnf* in adipose tissue (67). Similarly, obese men with significant weight reduction through a balanced-nutrition intervention also showed decreased methylation levels (68). Similar to the case

with *LEP* methylation, hypermethylation at the *Tnf* may occur as an adaptive mechanism to prevent further production of TNF α in obesity.

In addition to these sites, global profiling studies have detected profound changes in DNA methylation at multiple loci in obesity and T2D (Table 1). Studies of monozygotic twins discordant for T2D identified differential methylation at 7,046 genetic loci, including at candidate genes for T2D identified through GWAS such as *PPARG*, *IRS1*, *TCF7L2*, and *KCNQ1* (69). Three independent studies found DNA hypermethylation at the CpGs near *HIF3A* (70–72) in relation to BMI. This gene encodes a protein that is part of the heterodimeric hypoxia-inducible factor (HIF) transcriptional complex, which regulates many adaptive responses to hypoxia. The specific role of *HIF3A* in adipose biology is not well-known, but adipocyte-specific depletion of *Hif1a* in the HIF heterodimer improved insulin sensitivity in the context of a high-fat diet (73).

Additionally, differential methylation has been identified at adipose biology-related genes (e.g., *FTO*, *TCF7L2*, *IRS1*, *CCL18*, and *SPP1*) in obesity and T2D (69). A recent mouse adipocyte methylome study identified a number of differentially methylated regions in diet-induced obesity, some of which negatively correlate with gene expression changes (e.g., *Pck1*, *Tcf7l2*, and *Akt2*) (74). Cross-species analysis identified 170 differentially methylated regions that are conserved in human obesity, and 30 of them (e.g., *Mkl1*, *KCNA3*, and *Etaa1*) overlap with SNPs or nearby proxies that are associated with human T2D genetic risk. The authors integrated the DNA methylome with other chromatin modification maps, transcription localization maps, and disease associations (SNP/expression quantitative trait loci) to reveal DNA methylation events that might be more functionally relevant to disease susceptibility.

Genome-wide studies provide a powerful tool to discover changes in DNA methylation that might be functionally relevant to human obesity and T2D. However, they have a few major limitations. A majority of profiling studies, especially human studies, use an array-based method that covers a fraction of the CpG sites, being biased toward promoters and strongly underrepresenting distal regulatory elements. Base pair-resolution studies will be necessary in the future. Also, it should be noted that there is little overlap among the differentially modified gene loci between studies. Furthermore, it will be of great importance to address the causality of individual methylation events and follow up on the metabolic function of the proteins encoded by affected genes.

DNMT AND TET PROTEINS IN ADIPOSE BIOLOGY

Emerging evidence indicates that DNMTs are directly involved in regulating metabolic function in addition to developmental processes. The basal level of Dnmt1 and -3a is modestly high, while that of -3b is barely detectable in various mouse adipose tissues. Adipose DNMT levels are significantly increased in diet-induced obesity as well as in genetically obese *ob/ob* mice (75). Dnmt3a-overexpressor

mice on a high-fat diet have increased expression of inflammatory cytokines such as TNF- α and MCP-1 (75). As discussed earlier, DNMT1-mediated hypermethylation suppresses *Adipoq* expression in obesity (57). Adipose Dnmt3a plays a causal role in the development of insulin resistance in mice, as evidenced by adipose-specific deficiency of Dnmt3a conferring protection from diet-induced metabolic dysregulation independent of body weight or adiposity (64). Future studies should be conducted and followed up to determine whether there is a conserved role for DNMT3A in human insulin resistance.

Consistently, pharmacological DNMT inhibition improves insulin resistance both in vitro and in vivo (57,64), suggesting that DNMT inhibition can be an attractive therapeutic approach for metabolic disorders. Notably, administration of pan-inhibitors of histone deacetylase exerts beneficial metabolic effects in both mice and humans, such as increased energy expenditure, insulin sensitivity, and secretion (76–79). Together, these studies provide proof of principle that targeting epigenetic issues can be considered for therapeutic intervention to approach metabolic disorders.

Emerging evidence suggests that the TET proteins play an important metabolic function in adipocytes. All three TETs are expressed in mouse adipose tissue, but only Tet2 expression is reduced in diet-induced obesity. The expression of TET1 and TET2 is diminished in adipose stem cells from obese subjects, concurrent with a reduction of global 5hmC levels (80). It is noteworthy that global 5hmC levels are downregulated in blood samples from patients with diabetes, and this is dependent on TET2 action (81); this further suggests that altered TET2 action may influence glucose homeostasis. PPAR γ and the TET proteins appear to functionally and physically interact (34). During adipogenesis, PPAR γ , via the physical interaction with TET1, increases local demethylation around PPAR γ -binding sites (27). In mature adipocytes, TET2 facilitates the transcriptional activity of PPAR γ and insulin-sensitizing efficacy of PPAR γ agonist by sustaining DNA binding of PPAR γ at certain target loci (34). It is noteworthy that global 5hmC levels are downregulated in blood samples from patients with diabetes, further demonstrating that TET2 plays a necessary role in maintaining glucose homeostasis as a downstream effector of AMPK, especially in the oncogenic state (81). Together, these studies suggest that TET2 is a critical epigenetic sensor/regulator of glucose in the cell.

CONCLUDING REMARKS

Accumulating evidence suggests that epigenetics, which sits at the interface of genetics and environment, plays a dynamic role in the regulation of metabolic processes. With the reversibility of epigenetic changes, drugs that target these changes hold great promise for the prevention, diagnosis, treatment, and prognosis of metabolic disorders; however, there are still several challenges to overcome (see OUTSTANDING QUESTIONS [below]). First, it is essential to gain a more accurate and comprehensive

understanding of DNA methylation events that are at the core of pathogenesis. Despite a plethora of studies reporting DNA methylation changes in association with disease state, we still lack information about which changes are core to the condition and which events drive the phenotype. Capturing more dynamic changes through base pair-resolution profiling during fine time course studies will be necessary. Second, target specificity needs to be carefully addressed. DNA methylation is involved in a broad spectrum of biological processes in multiple tissues and cell types. Although systemic administration of DNMT inhibitors improves the metabolic profile, it is still under investigation whether they have deleterious effects due to nonspecificity. Target-specific epigenetic editing studies in mouse models have been performed and will be needed to address this question. Third, more thorough biological validation in cells and animals will be critical. Some epigenetic changes may increase disease susceptibility, but some occur as a consequence of the disease phenotype. Thus, functional validation of individual DNA methylation events and machinery should be done to resolve the consequence/causality issue in a definite way. In conclusion, we seek to elucidate the reversible and treatable epigenetic changes that can be used for personalized medicine and targeted therapy for metabolic diseases.

OUTSTANDING QUESTIONS

What triggers the change in DNA (de)methylation and machinery? Epigenetic regulation operates at multiple levels, and little is known about which stimuli (e.g., nutritional signals and molecular and epigenetic regulators) drive the change.

How dynamic is the change in methylation? A vast majority of studies profiled the change between disease and nondisease states, but very few studies have examined reversibility. It is difficult to delineate which changes are initial, and likely contribute to the pathogenesis, and which are consequential. Cataloging the dynamic changes may help narrow down the list to causal and treatable epigenetic changes.

What confers target specificity? DNA methylation machinery does not bind to DNA in a sequence-specific manner. Identifying recruiting factors that target genomic loci will be critical to achieving specificity.

What is the role of DNA methylation in interindividual differences in disease susceptibility and drug efficacy? DNA methylation is highly variable between individuals, even in those with the same genetic content, as evidenced by monozygotic twin studies. Investigating which changes are important to etiology and efficacy may identify new therapeutic approaches.

What is the role of metabolic cofactors in disease-associated DNA methylation? Epigenetics is regulated at multiple levels, and several key metabolites function as cofactors. DNMTs use *S*-adenosyl-*L*-methionine, generated by the methionine cycle, as the methyl donor, whereas TET enzymes require α -ketoglutarate, a key by-product of the tricarboxylic acid cycle. A change in metabolic state

would affect the concentration of these metabolites in cells and modulate the enzymatic activity of DNMTs and TETs. Understanding the regulatory function and mechanism of DNA (de)methylation at the cofactor levels will be crucial for developing a nutritional approach to therapy.

Funding. This work was supported by National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, grant R01 DK116008 (to S.K.).

Duality of Interest. No potential conflicts of interest relevant to this article were reported.

References

1. Lotta LA, Gulati P, Day FR, et al.; EPIC-InterAct Consortium; Cambridge FPLD1 Consortium. Integrative genomic analysis implicates limited peripheral adipose storage capacity in the pathogenesis of human insulin resistance. *Nat Genet* 2017;49:17–26
2. McCarthy MI. Genomics, type 2 diabetes, and obesity. *N Engl J Med* 2010;363:2339–2350
3. Voight BF, Scott LJ, Steinthorsdottir V, et al.; MAGIC investigators; GIANT Consortium. Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. *Nat Genet* 2010;42:579–589
4. Morris AP, Voight BF, Teslovich TM, et al.; Wellcome Trust Case Control Consortium; Meta-Analyses of Glucose and Insulin-related traits Consortium (MAGIC) Investigators; Genetic Investigation of Anthropometric Traits (GIANT) Consortium; Asian Genetic Epidemiology Network–Type 2 Diabetes (AGEN-T2D) Consortium; South Asian Type 2 Diabetes (SAT2D) Consortium; DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium. Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. *Nat Genet* 2012;44:981–990
5. Zeggini E, Scott LJ, Saxena R, et al.; Wellcome Trust Case Control Consortium. Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. *Nat Genet* 2008;40:638–645
6. Zhao J, Goldberg J, Bremner JD, Vaccarino V. Global DNA methylation is associated with insulin resistance: a monozygotic twin study. *Diabetes* 2012;61:542–546
7. Jones PA. Functions of DNA methylation: islands, start sites, gene bodies and beyond. *Nat Rev Genet* 2012;13:484–492
8. Barrès R, Osler ME, Yan J, et al. Non-CpG methylation of the PGC-1 α promoter through DNMT3B controls mitochondrial density. *Cell Metab* 2009;10:189–198
9. Lister R, Pelizzola M, Dowen RH, et al. Human DNA methylomes at base resolution show widespread epigenomic differences. *Nature* 2009;462:315–322
10. Yan J, Zierath JR, Barrès R. Evidence for non-CpG methylation in mammals. *Exp Cell Res* 2011;317:2555–2561
11. Robertson KD. DNA methylation and human disease. *Nat Rev Genet* 2005;6:597–610
12. Barrès R, Yan J, Egan B, et al. Acute exercise remodels promoter methylation in human skeletal muscle. *Cell Metab* 2012;15:405–411
13. Barres R, Kirchner H, Rasmussen M, et al. Weight loss after gastric bypass surgery in human obesity remodels promoter methylation. *Cell Reports* 2013;3:1020–1027
14. Bhutani N, Burns DM, Blau HM. DNA demethylation dynamics. *Cell* 2011;146:866–872
15. Benner C, Isoda T, Murre C. New roles for DNA cytosine modification, eRNA, anchors, and superanchors in developing B cell progenitors. *Proc Natl Acad Sci U S A* 2015;112:12776–12781
16. Jaenisch R, Bird A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. *Nat Genet* 2003;33(Suppl.):245–254

17. Ponnaluri VKC, Ehrlich KC, Zhang G, et al. Association of 5-hydroxymethylation and 5-methylation of DNA cytosine with tissue-specific gene expression. *Epigenetics* 2017;12:123–138
18. Smith ZD, Meissner A. DNA methylation: roles in mammalian development. *Nat Rev Genet* 2013;14:204–220
19. Pinnick KE, Karpe F. DNA methylation of genes in adipose tissue. *Proc Nutr Soc* 2011;70:57–63
20. D'Alessio AC, Weaver IC, Szyf M. Acetylation-induced transcription is required for active DNA demethylation in methylation-silenced genes. *Mol Cell Biol* 2007;27:7462–7474
21. Sakamoto H, Kogo Y, Ohgane J, et al. Sequential changes in genome-wide DNA methylation status during adipocyte differentiation. *Biochem Biophys Res Commun* 2008;366:360–366
22. Taylor SM, Jones PA. Multiple new phenotypes induced in 10T1/2 and 3T3 cells treated with 5-azacytidine. *Cell* 1979;17:771–779
23. Bowers RR, Kim JW, Otto TC, Lane MD. Stable stem cell commitment to the adipocyte lineage by inhibition of DNA methylation: role of the BMP-4 gene. *Proc Natl Acad Sci U S A* 2006;103:13022–13027
24. Londoño Gentile T, Lu C, Lodato PM, et al. DNMT1 is regulated by ATP-citrate lyase and maintains methylation patterns during adipocyte differentiation. *Mol Cell Biol* 2013;33:3864–3878
25. Yang X, Wu R, Shan W, Yu L, Xue B, Shi H. DNA methylation biphasically regulates 3T3-L1 preadipocyte differentiation. *Mol Endocrinol* 2016;30:677–687
26. Chen Y-S, Wu R, Yang X, et al. Inhibiting DNA methylation switches adipogenesis to osteoblastogenesis by activating Wnt10a. *Sci Rep* 2016;6:25283
27. Fujiki K, Shinoda A, Kano F, Sato R, Shirahige K, Murata M. PPAR γ -induced PARylation promotes local DNA demethylation by production of 5-hydroxymethylcytosine. *Nat Commun* 2013;4:2262
28. Li J, Zhang N, Huang X, et al. Dexamethasone shifts bone marrow stromal cells from osteoblasts to adipocytes by C/EBP α promoter methylation. *Cell Death Dis* 2013;4:e832
29. Matsumura Y, Nakaki R, Inagaki T, et al. H3K4/H3K9me3 bivalent chromatin domains targeted by lineage-specific DNA methylation pauses adipocyte differentiation. *Mol Cell* 2015;60:584–596
30. Yokomori N, Tawata M, Onaya T. DNA demethylation during the differentiation of 3T3-L1 cells affects the expression of the mouse GLUT4 gene. *Diabetes* 1999;48:685–690
31. Dubois-Chevalier J, Oger F, Dehondt H, et al. A dynamic CTCF chromatin binding landscape promotes DNA hydroxymethylation and transcriptional induction of adipocyte differentiation. *Nucleic Acids Res* 2014;42:10943–10959
32. Yu P, Ji L, Lee KJ, et al. Subsets of visceral adipose tissue nuclei with distinct levels of 5-hydroxymethylcytosine. *PLoS One* 2016;11:e0154949
33. Yoo Y, Park JH, Weigel C, et al. TET-mediated hydroxymethylcytosine at the Ppar γ locus is required for initiation of adipogenic differentiation. *Int J Obes* 2017;41:652–659
34. Bian F, Ma X, Villivalam SD, et al. TET2 facilitates PPAR γ agonist-mediated gene regulation and insulin sensitization in adipocytes. *Metabolism* 2018;89:39–47
35. Gupta RK, Arany Z, Seale P, et al. Transcriptional control of preadipocyte determination by Zfp423. *Nature* 2010;464:619–623
36. Shao M, Ishibashi J, Kusminski CM, et al. Zfp423 maintains white adipocyte identity through suppression of the beige cell thermogenic gene program. *Cell Metab* 2016;23:1167–1184
37. Yang QY, Liang JF, Rogers CJ, Zhao JX, Zhu MJ, Du M. Maternal obesity induces epigenetic modifications to facilitate Zfp423 expression and enhance adipogenic differentiation in fetal mice. *Diabetes* 2013;62:3727–3735
38. Liang X, Yang Q, Fu X, et al. Maternal obesity epigenetically alters visceral fat progenitor cell properties in male offspring mice. *J Physiol* 2016;594:4453–4466
39. Inagaki T, Sakai J, Kajimura S. Transcriptional and epigenetic control of brown and beige adipose cell fate and function. *Nat Rev Mol Cell Biol* 2016;17:480–495
40. Lim YC, Chia SY, Jin S, Han W, Ding C, Sun L. Dynamic DNA methylation landscape defines brown and white cell specificity during adipogenesis. *Mol Metab* 2016;5:1033–1041
41. Shore A, Karamitri A, Kemp P, Speakman JR, Lomax MA. Role of Ucp1 enhancer methylation and chromatin remodelling in the control of Ucp1 expression in murine adipose tissue. *Diabetologia* 2010;53:1164–1173
42. Kiskinis E, Hallberg M, Christian M, et al. RIP140 directs histone and DNA methylation to silence Ucp1 expression in white adipocytes. *EMBO J* 2007;26:4831–4840
43. Yang Q, Liang X, Sun X, et al. AMPK/ α -ketoglutarate axis dynamically mediates DNA demethylation in the Prdm16 promoter and brown adipogenesis. *Cell Metab* 2016;24:542–554
44. Sun W, Dong H, Becker AS, et al. Cold-induced epigenetic programming of the sperm enhances brown adipose tissue activity in the offspring. *Nat Med* 2018;24:1372–1383
45. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. *Nat Rev Immunol* 2011;11:85–97
46. Pan WW, Myers MG Jr. Leptin and the maintenance of elevated body weight. *Nat Rev Neurosci* 2018;19:95–105
47. Myers MG Jr, Leibel RL, Seeley RJ, Schwartz MW. Obesity and leptin resistance: distinguishing cause from effect. *Trends Endocrinol Metab* 2010;21:643–651
48. Marchi M, Lisi S, Curcio M, et al. Human leptin tissue distribution, but not weight loss-dependent change in expression, is associated with methylation of its promoter. *Epigenetics* 2011;6:1198–1206
49. Melzner I, Scott V, Dorsch K, et al. Leptin gene expression in human preadipocytes is switched on by maturation-induced demethylation of distinct CpGs in its proximal promoter. *J Biol Chem* 2002;277:45420–45427
50. Stöger R. In vivo methylation patterns of the leptin promoter in human and mouse. *Epigenetics* 2006;1:155–162
51. Milagro FI, Campión J, García-Díaz DF, Goyenechea E, Paternain L, Martínez JA. High fat diet-induced obesity modifies the methylation pattern of leptin promoter in rats. *J Physiol Biochem* 2009;65:1–9
52. Fan C, Liu X, Shen W, Deckelbaum RJ, Qi K. The regulation of leptin, leptin receptor and pro-opiomelanocortin expression by N-3 PUFAs in diet-induced obese mice is not related to the methylation of their promoters. *Nutr Metab (Lond)* 2011;8:31
53. Zwamborn RAJ, Sliker RC, Mulder PC, et al. Prolonged high-fat diet induces gradual and fat depot-specific DNA methylation changes in adult mice. *Sci Rep* 2017;7:43261
54. Shen W, Wang C, Xia L, et al. Epigenetic modification of the leptin promoter in diet-induced obese mice and the effects of N-3 polyunsaturated fatty acids. *Sci Rep* 2014;4:5282
55. Maeda N, Shimomura I, Kishida K, et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. *Nat Med* 2002;8:731–737
56. Wang ZV, Scherer PE. Adiponectin, the past two decades. *J Mol Cell Biol* 2016;8:93–100
57. Kim AY, Park YJ, Pan X, et al. Obesity-induced DNA hypermethylation of the adiponectin gene mediates insulin resistance. *Nat Commun* 2015;6:7585
58. Houde AA, Légaré C, Biron S, et al. Leptin and adiponectin DNA methylation levels in adipose tissues and blood cells are associated with BMI, waist girth and LDL-cholesterol levels in severely obese men and women. *BMC Med Genet* 2015;16:29
59. Haghiac M, Basu S, Presley L, Serre D, Catalano PM, Hauguel-de Mouzon S. Patterns of adiponectin expression in term pregnancy: impact of obesity. *J Clin Endocrinol Metab* 2014;99:3427–3434
60. Fon Tacer K, Bookout AL, Ding X, et al. Research resource: comprehensive expression Atlas of the fibroblast growth factor system in adult mouse. *Mol Endocrinol* 2010 Oct;24:2050–2064
61. Lee DV, Li D, Yan Q, et al. Fibroblast growth factor 21 improves insulin sensitivity and synergizes with insulin in human adipose stem cell-derived (hASC) adipocytes. *PLoS One* 2014;9:e111767
62. Minard AY, Tan SX, Yang P, et al. mTORC1 is a major regulatory node in the FGF21 signaling network in adipocytes. *Cell Reports* 2016;17:29–36

63. Ge X, Chen C, Hui X, Wang Y, Lam KS, Xu A. Fibroblast growth factor 21 induces glucose transporter-1 expression through activation of the serum response factor/Ets-like protein-1 in adipocytes. *J Biol Chem* 2011;286:34533–34541
64. You D, Nilsson E, Tenen DE, et al. Dnmt3a is an epigenetic mediator of adipose insulin resistance. *eLife* 2017;6:e30766
65. Coppack SW. Pro-inflammatory cytokines and adipose tissue. *Proc Nutr Soc* 2001;60:349–356
66. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor- α in human obesity and insulin resistance. *J Clin Invest* 1995;95:2409–2415
67. Cordero P, Campion J, Milagro FI, et al. Leptin and TNF- α promoter methylation levels measured by MSP could predict the response to a low-calorie diet. *J Physiol Biochem* 2011;67:463–470
68. Campi3n J, Milagro FI, Goyenechea E, Mart3nez JA. TNF- α promoter methylation as a predictive biomarker for weight-loss response. *Obesity (Silver Spring)* 2009;17:1293–1297
69. Nilsson E, Jansson PA, Perfilov A, et al. Altered DNA methylation and differential expression of genes influencing metabolism and inflammation in adipose tissue from subjects with type 2 diabetes. *Diabetes* 2014;63:2962–2976
70. R3nn T, Volkov P, Gillberg L, et al. Impact of age, BMI and HbA1c levels on the genome-wide DNA methylation and mRNA expression patterns in human adipose tissue and identification of epigenetic biomarkers in blood. *Hum Mol Genet* 2015;24:3792–3813
71. Agha G, Houseman EA, Kelsey KT, Eaton CB, Buka SL, Loucks EB. Adiposity is associated with DNA methylation profile in adipose tissue. *Int J Epidemiol* 2015;44:1277–1287
72. Dick KJ, Nelson CP, Tsaprouni L, et al. DNA methylation and body-mass index: a genome-wide analysis. *Lancet* 2014;383:1990–1998
73. Jiang C, Qu A, Matsubara T, et al. Disruption of hypoxia-inducible factor 1 in adipocytes improves insulin sensitivity and decreases adiposity in high-fat diet-fed mice. *Diabetes* 2011;60:2484–2495
74. Multhaup ML, Seldin MM, Jaffe AE, et al. Mouse-human experimental epigenetic analysis unmasks dietary targets and genetic liability for diabetic phenotypes. *Cell Metab* 2015;21:138–149
75. Kamei Y, Suganami T, Ehara T, et al. Increased expression of DNA methyltransferase 3a in obese adipose tissue: studies with transgenic mice. *Obesity (Silver Spring)* 2010;18:314–321
76. Christensen DP, Dahllof M, Lundh M, et al. Histone deacetylase (HDAC) inhibition as a novel treatment for diabetes mellitus. *Mol Med* 2011;17:378–390
77. Daneshpajoo M, Bacos K, Bysani M, et al. HDAC7 is overexpressed in human diabetic islets and impairs insulin secretion in rat islets and clonal beta cells. *Diabetologia* 2017;60:116–125
78. Sharma S, Taliyan R. Histone deacetylase inhibitors: future therapeutics for insulin resistance and type 2 diabetes. *Pharmacol Res* 2016;113:320–326
79. Ye J. Improving insulin sensitivity with HDAC inhibitor. *Diabetes* 2013;62:685–687
80. P3rez LM, Bernal A, de Lucas B, et al. Altered metabolic and stemness capacity of adipose tissue-derived stem cells from obese mouse and human. *PLoS One* 2015;10:e0123397
81. Wu D, Hu D, Chen H, et al. Glucose-regulated phosphorylation of TET2 by AMPK reveals a pathway linking diabetes to cancer. *Nature* 2018;559:637–641